


Ask a doctor about a prescription for CEFEPIMA NORMON 2 g POWDER AND SOLVENT FOR INJECTION AND INFUSION SOLUTION
Package Leaflet: Information for the User
Cefepime NORMON 2 g powder and solvent for solution for injection and infusionand for infusionEFG
Read all of this leaflet carefully before you start using this medicine.
Contents of the pack:
Cefepime NORMON is an antibiotic that is administered by infusion (drip) or by intravenous injection.
Cefepime belongs to the group of antibiotics called "cephalosporins". These antibiotics are quite similar to penicillin.
Antibiotics are used to treat bacterial infections and are not effective against viral infections such as the flu or common cold. It is essential that you follow the instructions regarding dosage, administration interval, and treatment duration as indicated by your doctor. Do not store or reuse this medication. If you have any leftover antibiotic after completing treatment, return it to the pharmacy for proper disposal. Do not throw medicines down the drain or in the trash. |
Cefepime NORMON is effective against certain types of bacteria that are sensitive to the active substance cefepime.
It is suitable for the treatment of infections in adults such as:
It can also be used to help prevent infections after abdominal surgery.
It is suitable for the treatment of infections in children such as:
Do not use Cefepime NORMON:
In case of doubt, consult your doctor or pharmacist.
Warnings and precautions
Consult your doctor or pharmacist before starting to use cefepime if:
If you experience any of these situations, your doctor may want to change the treatment or give you special warnings.
Using Cefepime NORMON with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
This is important because some medicines should not be taken with Cefepime NORMON. In particular, tell your doctor if:
Pregnancyandbreast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine. Cefepime will only be administered if the expected benefit to the mother is greater than the unknown risks to the fetus.
Do not breastfeed if you are using this medicine because small amounts of it pass into breast milk and therefore to the infant.
Consult your doctor or pharmacist before using any medicine.
Driving and using machines
No studies have been conducted to determine the effects on the ability to drive and use machines. However, side effects may occur that can affect the ability to drive or use machines (see section 4).
Follow exactly the administration instructions for this medicine as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Cefepime is usually administered by a doctor or nurse. If in doubt, consult your doctor or pharmacist again.
It is administered:
By intravenous injection (over 3-5 minutes) or through a drip (over 30 minutes) into a vein (infusion)
The dose of Cefepime will be determined by your doctor based on age, weight, severity of the infection, and kidney function. Your doctor will explain this to you.
If you use more Cefepime NORMON than you should:
Since it will be a doctor or nurse who administers Cefepime, it is unlikely that you will receive an incorrect dose. However, if you experience side effects or think you have received too much, tell your doctor immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to use Cefepime NORMON
If you think you have not received a dose of Cefepime, tell your doctor immediately.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
You must inform your doctor immediately if you notice any of the following:
Uncommon side effects (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Side effects of unknown frequency
Other possible side effects:
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Low red blood cell count, increased white blood cell count, changes in blood coagulation parameters.
Uncommon side effects (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Side effects of unknown frequency
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if it is not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging after "EXP". The expiry date is the last day of the month indicated.
Do not store above 30°C. Store in the carton to protect from light.
The storage conditions for the reconstituted/diluted solutions of the medicine can be found at the end of the leaflet "This information is intended only for healthcare professionals".
Medicines should not be disposed of via wastewater or household waste. Dispose of the packaging and any unused medicine in the SIGRE collection point at the pharmacy. If in doubt, consult your pharmacist on how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Cefepima NORMON
Each vial contains 2 g of cefepima (as cefepima dihydrochloride monohydrate)
The other component (excipient) is L-arginine
Each ampoule contains water for injectable preparations
Appearance of the Product and Container Content
Cefepima NORMON is a white or almost white powder for injectable solution and perfusion, packaged in glass vials closed with an elastomer stopper and a flip-off cap.
The vials are packaged in cardboard boxes.
Presentation: 1 and 50 vials.
Only some package sizes may be commercialized
Marketing Authorization Holder and Manufacturer
LABORATORIOS NORMON, S.A.
Ronda de Valdecarrizo, 6 – 28760 Tres Cantos – Madrid (SPAIN)
Date of the last revision of this prospectus: May 2014
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
--------------------------------------------------------------------------------------------------------------------
This information is intended only for medical professionals or healthcare professionals:
Cefepima NORMON 2 g powder and solvent for injectable solution and perfusion EFG
This is an extract from the Summary of Product Characteristics to help with the administration of Cefepima NORMON. To determine the suitability of its use in a particular patient, the doctor must be familiar with the Summary of Product Characteristics.
For slow intravenous injection/perfusion.
INCOMPATIBILITIES WITH DILUENTS AND OTHER MEDICINES
Cefepima NORMON solutions must notbe mixed with the following antibiotics: metronidazole, vancomycin, gentamicin, tobramycin sulfate, and netilmicin sulfate, as physical or chemical incompatibilities may occur. If concomitant treatment is indicated, these antibiotics must be administered separately.
INSTRUCTIONS FOR USE, HANDLING, AND DISPOSAL
Aseptic techniques must be used to reconstitute the solution. The reconstituted solution must be administered immediately after preparation.
Inspect the vial before use. It must only be used if the solution is free of particles.
Only use transparent solutions.
As with other cephalosporins, cefepima solutions may acquire a yellow to amber color, depending on storage conditions. However, this has no negative effect on the product's efficacy.
Disposal of unused medication and all materials that have come into contact with it will be carried out in accordance with local regulations.
Method of Administration:
Intravenous Administration:
For direct IV injection, the contents of the ampoule are dissolved in 5 or 10 ml of water for injectable preparations, 5% glucose solution for perfusion, or 9 mg/ml (0.9%) sodium chloride solution for perfusion, as indicated in the following table. Reconstitution must be carried out with immediate and vigorous agitation until the product is completely dissolved after adding the volume of solvent used to reconstitute the vial, avoiding diffusion of the solvent into the powder without dissolving it. The prepared solution is injected slowly over 3 to 5 minutes or directly into a vein or through a cannula of an IV perfusion system while the patient is receiving an IV perfusion with a compatible solution.
For IV perfusions, the powder is dissolved as described for direct IV injections. An appropriate amount of the prepared solution is added to an IV perfusion container containing a compatible IV perfusion solution.
Cefepima NORMON, once reconstituted, is compatible with the following perfusion solutions: water for injectable preparations, 9 mg/ml (0.9%) sodium chloride solution for perfusion, 5% glucose solution for perfusion, 10% glucose solution for perfusion, 1/6M sodium lactate solution for perfusion, 5% glucose and 9 mg/ml (0.9%) sodium chloride solution for perfusion, Ringer's lactate solution, and 5% glucose and Ringer's lactate solution for perfusion. Reconstituted and diluted solutions must be administered immediately after preparation.
Posology:
Adults and Adolescents with a Body Weight Over 40 kg (Approximately Over 12 Years):
Severity of Infection Dosage Interval | Dose and Route of Administration | Dosage Interval |
Mild to Moderate Infections | 1 g IV | 12h |
Moderate to Severe Skin and Soft Tissue Infections | 2 g IV | 12h |
Severe Infections | 2 g IV | 12h |
Life-Threatening Infections |
| 8h |
Pediatric Population:
Pneumonia, urinary tract infections, skin and soft tissue infections: 50 mg/kg every 12 hours for 10 days. For severe infections, the dose may be administered every 8 hours.
Elderly Patients:
No dose adjustment is required, except in cases of renal insufficiency.
Hepatic Insufficiency in Adults:
No dose adjustment is required in patients with hepatic insufficiency.
Renal Insufficiency in Adults:
The recommended initial dose in patients with renal insufficiency (except in cases of dialysis, see below) is the same as that for patients with normal renal function. The following table shows the maintenance dosing for adult patients with renal dysfunction:
Creatinine Clearance (ml/min) | Recommended Maintenance Dose (Usual dose, no dose adjustment needed) | ||
> 50 | 2 g every 8 h | 2 g every 12 h | 1 g every 12 h |
30-50 | 2 g every 12 h | 2 g every 24 h | 1 g every 24 h |
11-29 | 2 g every 24 h | 1 g every 24 h | 500 mg every 24 h |
≤ 10 | 1 g every 24 h | 500 mg every 24 h | 250 mg every 24 h |
Hemodialysis | 500 mg every 24 h | 500 mg every 24 h | 500 mg every 24 h |
Dialyzed Patients:
The recommended dose is 1 g of cefepima on the first day of treatment, followed by 500 mg/day in all infections, except febrile neutropenia. On dialysis days, cefepima must be administered after hemodialysis. Whenever possible, cefepima should be administered at the same time every day.
In cases of continuous ambulatory peritoneal dialysis, cefepima may be administered at the same doses recommended for patients with normal renal function, but only at 48-hour intervals.
Children with Renal Insufficiency:
Maintenance dose in children between 2 months and 12 years with renal insufficiency:
Creatinine Clearance (ml/min) | Recommended Maintenance Dose in Children > 2 Months to 12 Years |
> 50 | Usual dose, no dose adjustment needed: 50 mg/kg every 8h / 50 mg/kg every 12h |
30-50 | 50 mg/kg every 12h / 50 mg/kg every 24h |
11-29 | 50 mg/kg every 24h / 25 mg/kg every 24h |
≤10 | 25 mg/kg every 24h / 12.5 mg/kg every 24h |
Duration of Treatment:
In general, treatment should always be continued for a few days after the reduction of fever and the resolution of pathological symptoms. The duration of treatment is usually 7 to 10 days; however, longer treatment may be necessary for more severe infections. For the empirical treatment of febrile neutropenia, the duration of treatment is generally 7 days or until the resolution of neutropenia.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for CEFEPIMA NORMON 2 g POWDER AND SOLVENT FOR INJECTION AND INFUSION SOLUTION – subject to medical assessment and local rules.